Skip to main content
SpringerLink
Log in

Ketoconazole Foam — Connetics

Connetics Ketoconazole Foam

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Connetics Corporation. Connetics Presents Scientific Posters at American Academy of Dermatology’s 61st Annual Meeting. Media Release: 20 Mar 2003. Available from URL: http://www.connetics.com

    Google Scholar 

  2. Koller T, Rocco-Wood S, Yaroshinsky A, et al. A randomized, open-label study to evaluate the comparative bioavailability of ketoconazole foam, 2%, versus ketoconazole 2% cream in the treatment of moderate to severe seborrheic dermatitis. 61st Annual Meeting of the American Academy of Dermatology: 159, 21 Mar 2003

  3. Huang X, Tanojo H, Lenn J. Impact of formulation on ketoconazole skin penetration and drug distribution in vitro. 61st Annual Meeting of the American Academy of Dermatology: 113, 21 Mar 2003

  4. Huang X, Tanojo H, Lenn J, et al. Enhanced ketoconazole bioavailability from a foam formulation: contribution of biological and nonbiological components. 61st Annual Meeting of the American Academy of Dermatology: 113, 21 Mar 2003

  5. Connetics Corporation. Connetics Announces Positive Extina Phase III Trial Results. Media Release: 23 Apr 2003. Available from URL: http://www.connetics.com

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ketoconazole Foam — Connetics. Drugs R&D 4, 323–325 (2003). https://doi.org/10.2165/00126839-200304050-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304050-00009

Keywords

Search

Navigation